World's Best Scientists 2026 revealed!
Anthony W. Tolcher

Anthony W. Tolcher

D-Index & Metrics

Medicine

D-Index
86
Citations
30874
World Ranking
14006
National Ranking
7107

Overview

Anthony W. Tolcher is affiliated with Texas Oncology in the United States. Their research contributions primarily lie within the fields of Medicine and Biochemistry, Genetics and Molecular Biology. They have a significant focus on oncology and molecular biology with additional expertise covering radiology, nuclear medicine and imaging, immunology, and pulmonary and respiratory medicine.

Their work touches on several specialized subjects including cancer immunotherapy and biomarkers, monoclonal and polyclonal antibodies research, HER2/EGFR in cancer research, CAR-T cell therapy research, cancer research and treatments, peptidase inhibition and analysis, and colorectal cancer treatments and studies.

Frequent collaborators in their research include Alexander I. Spira, Erika Hamilton, Timothy A. Yap, Patricia LoRusso, and Melissa L. Johnson. The scholar has published extensively in respected venues, with notable recurrent publication outlets being:

  • Journal of Clinical Oncology
  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Clinical Cancer Research
  • Annals of Oncology

Representative recent papers authored or co-authored by Anthony W. Tolcher include:

  • Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial (2022), Journal for ImmunoTherapy of Cancer
  • First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01 (2023), Journal of Clinical Oncology
  • Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study (2024), Journal of Clinical Oncology
  • First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation. (2022), Journal of Clinical Oncology
  • First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors (2021), Clinical Cancer Research

Best Publications

  • Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

    Mark E. Davis;Jonathan E Zuckerman;Chung Hang J Choi;David Seligson

  • Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

    Manuel Hidalgo;Lillian L. Siu;John Nemunaitis;Jinee Rizzo

  • First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

    Timothy A. Yap;Li Yan;Amita Patnaik;Ivy Fearen

  • Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma

    Randy D. Gascoyne;Sheryle A. Adomat;Sheryle A. Adomat;Stanislaw Krajewski;Stanislaw Krajewski;Maryla Krajewska;Maryla Krajewska

  • Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

    Amita Patnaik;S. Peter Kang;Drew Rasco;Kyriakos P. Papadopoulos

  • Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

    Amita Patnaik;Lee S. Rosen;Sara M. Tolaney;Anthony W. Tolcher

  • The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer

    Toshio Shimizu;Anthony W. Tolcher;Kyriakos P. Papadopoulos;Muralidhar Beeram

  • Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.

    Alain C. Mita;Louis J. Denis;Eric K. Rowinsky;Johann S. DeBono

  • Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

    Anthony W. Tolcher;Monica Mita;Neal J. Meropol;Margaret von Mehren

  • Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

    A W Tolcher;S L Gerson;L Denis;C Geyer

  • Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

    Monica M. Mita;Alain C. Mita;Quincy S. Chu;Eric K. Rowinsky

  • Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

    Anthony W. Tolcher;John Sarantopoulos;Amita Patnaik;Kyriakos Papadopoulos

  • Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA

    Jonathan E. Zuckerman;Ismael Gritli;Anthony Tolcher;Jeremy D. Heidel

  • Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

    Anthony W. Tolcher;Steven Sugarman;Karen A. Gelmon;Roger Cohen

  • First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

    Ryan J. Sullivan;Jeffrey R. Infante;Filip Janku;Deborah Jean Lee Wong

  • Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

    Anthony W. Tolcher;Alain Mita;Lionel D. Lewis;Christopher R. Garrett

  • Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study

    Anthony W. Tolcher;Leonel Ochoa;Lisa A. Hammond;Amita Patnaik

  • Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

    Anthony W. Tolcher;Wells A. Messersmith;Stanislaw M. Mikulski;Kyriakos P. Papadopoulos

  • Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

    Sant P. Chawla;Arthur P. Staddon;Laurence H. Baker;Scott M. Schuetze

  • A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

    Shahneen K. Sandhu;Kyri Papadopoulos;Peter C. Fong;Amita Patnaik

Frequent Co-Authors

Amita Patnaik
Amita Patnaik University of Chicago
Patricia LoRusso
Patricia LoRusso Yale University
Geoffrey I. Shapiro
Geoffrey I. Shapiro Harvard University
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Keith T. Flaherty
Keith T. Flaherty Harvard University
Jeffrey R. Infante
Jeffrey R. Infante Janssen (Belgium)
Ryan J. Sullivan
Ryan J. Sullivan Harvard University
Howard A. Burris
Howard A. Burris Sarah Cannon Research Institute
George D. Demetri
George D. Demetri Dana-Farber Cancer Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Choosing a career in medicine opens a wide array of academic and professional options beyond traditional MD or DO routes. Today, online education has made it easier than ever for students and professionals to advance or specialize in various healthcare fields.

For registered nurses seeking an advanced practice role, rn to fnp bridge programs offer a streamlined pathway to become a Family Nurse Practitioner. Alternatively, those interested in growing demand within nutrition and wellness might explore best online nutrition programs to step into roles like dietitian or health coach.

Many healthcare professionals view management as a fulfilling next step. Accredited graduate degrees such as online mha programs can prepare you for leadership in hospitals and health systems. For RNs balancing work and education, accelerated rn to bsn online without clinicals options are available, allowing career advancement with maximum flexibility.

Exploring these online degrees expands your potential career pathways, empowering you to shape a future in healthcare that fits your interests and schedule.

Best Scientists Citing Anthony W. Tolcher

Trending Scientists

Recently Published Articles